Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ERYTHROMYCIN BREATH TEST' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 103 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Eeckhoudt, SL; Desager, JP; Robert, AR; Leclercq, I; Verbeeck, RK; Horsman, Y
      Midazolam and cortisol metabolism before and after CYP3A induction in humans

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    2. Khaliq, Y; Gallicano, K; Tisdale, C; Carignan, G; Cooper, C; McCarthy, A
      Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    3. Boulton, DW; Arnaud, P; DeVane, CL
      A single dose of methadone inhibits cytochrome P-4503A activity in healthyvolunteers as assessed by the urinary cortisol ratio

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    4. Haas, CE; Kaufman, DC; DiCenzo, RC
      Effects of metronidazole on hepatic CYP3A4 activity

      PHARMACOTHERAPY
    5. Wacher, VJ; Salphati, L; Benet, LZ
      Active secretion and enterocytic drug metabolism barriers to drug absorption

      ADVANCED DRUG DELIVERY REVIEWS
    6. Weaver, RJ
      Assessment of drug-drug interactions concepts and approaches

      XENOBIOTICA
    7. Yasui-Furukori, N; Kondo, T; Kubota, T; Otake, H; Ohkubo, T; Nagasaki, T; Sugawara, K; Chiba, K; Otani, K; Kaneko, S
      No correlations between the urinary ratio of 6 beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    8. Daigle, JC; Hosgood, G; Foil, CS; Hunter, RP
      Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs

      AMERICAN JOURNAL OF VETERINARY RESEARCH
    9. Hirth, J; Watkins, PB; Strawderman, M; Schott, A; Bruno, R; Baker, LH
      The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

      CLINICAL CANCER RESEARCH
    10. Ozdemir, V; Kalow, W; Tang, BK; Paterson, AD; Walker, SE; Endrenyi, L; Kashuba, ADM
      Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

      PHARMACOGENETICS
    11. Streetman, DS; Bertino, JS; Nafziger, AN
      Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

      PHARMACOGENETICS
    12. Zaigler, M; Tantcheva-Poor, I; Fuhr, U
      Problems and perspectives of phenotyping for drug-metabolizing enzymes in man

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    13. Paine, MF; Davis, CL; Shen, DD; Marsh, CL; Raisys, VA; Thummel, KE
      Can oral midazolam predict oral cyclosporine disposition?

      EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    14. Yamamoto, N; Tamura, T; Kamiya, Y; Sekine, I; Kunitoh, H; Saijo, N
      Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol

      JOURNAL OF CLINICAL ONCOLOGY
    15. Doherty, MM; Pang, KS
      Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation

      PHARMACEUTICAL RESEARCH
    16. Gao, L; Ramzan, I; Baker, AB
      Potential use of pharmacological markers to quantitatively assess liver function during liver transplantation surgery

      ANAESTHESIA AND INTENSIVE CARE
    17. Slain, D; Pakyz, A; Israel, DS; Monroe, S; Polk, RE
      Variability in activity of hepatic CYP3A4 in patients infected with HIV

      PHARMACOTHERAPY
    18. Guengerich, FP
      Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics

      DRUG DEVELOPMENT RESEARCH
    19. Wieling, J; Tamminga, WJ; Sakiman, EP; Oosterhuis, B; Wemer, J; Jonkman, JHG
      Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening

      THERAPEUTIC DRUG MONITORING
    20. Lan, LB; Dalton, JT; Schuetz, EG
      Mdr1 limits CYP3A metabolism in vivo

      MOLECULAR PHARMACOLOGY
    21. McCune, JS; Hawke, RL; LeCluyse, EL; Gillenwater, HH; Hamilton, G; Ritchie, J; Lindley, C
      In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    22. Damkier, P; Brosen, K
      Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    23. Wandel, C; Witte, JS; Hall, JM; Stein, CM; Wood, AJJ; Wilkinson, GR
      CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5 '-promoter region polymorphism

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    24. Villeneuve, JP; L'Ecuyer, L; De Maeght, S; Bannon, P
      Prediction of cyclosporine clearance in liver transplant recipients by theuse of midazolam as a cytochrome P450 3A probe

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    25. Bastien, MC; Leblond, F; Pichette, V; Villeneuve, JP
      Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis

      CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
    26. Treluyer, JM
      The promise of therapeutic drug monitoring in HIV infection

      ANNALES DE MEDECINE INTERNE
    27. Schmider, J; Brockmoller, J; Arold, G; Bauer, S; Roots, I
      Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine

      PHARMACOGENETICS
    28. Kashuba, ADM; Nafziger, AN; Kearns, GL; Leeder, JS; Gotschall, R; Gaedigk, A; Bertino, JS
      Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity

      PHARMACOGENETICS
    29. Kudo, S; Ishizaki, T
      Pharmacokinetics of haloperidol - An update

      CLINICAL PHARMACOKINETICS
    30. de Wildt, SN; Kearns, GL; Leeder, JS; van den Anker, JN
      Cytochrome P450 3A - Ontogeny and drug disposition

      CLINICAL PHARMACOKINETICS
    31. Suri, A; Forbes, WP; Bramer, SL
      Effects of CYP3A inhibition on the metabolism of cilostazol

      CLINICAL PHARMACOKINETICS
    32. Kenworthy, KE; Bloomer, JC; Clarke, SE; Houston, JB
      CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    33. Min, DI; Ku, YM; Vichiendilokkul, A; Fleckenstein, LL
      A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers

      PHARMACOTHERAPY
    34. Polk, RE; Crouch, MA; Israel, DS; Pastor, A; Sadler, BM; Chittick, GE; Symonds, WT; Gouldin, W; Lou, Y
      Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men

      PHARMACOTHERAPY
    35. Schenker, S; Martin, RR; Hoyumpa, AM
      Antecedent liver disease and drug toxicity

      JOURNAL OF HEPATOLOGY
    36. Kaplan, B; Meier-Kriesche, HU; Napoli, KL; Kahan, BD
      Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients

      THERAPEUTIC DRUG MONITORING
    37. Munoz, AE; Miguez, C; Rubio, M; Bartellini, M; Levi, D; Podesta, A; Niselman, V; Terg, R
      Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration

      DIGESTIVE DISEASES AND SCIENCES
    38. Kharasch, ED; Mautz, D; Senn, T; Lentz, G; Cox, K
      Menstrual cycle variability in midazolam pharmacokinetics

      JOURNAL OF CLINICAL PHARMACOLOGY
    39. Provencher, SJ; Demers, C; Bastien, MC; Villeneuve, JP; Gascon-Barre, M
      Effect of cyclosporine A on cytochrome P-450-mediated drug metabolism in the partially hepatectomized rat

      DRUG METABOLISM AND DISPOSITION
    40. Ogg, MS; Williams, JM; Tarbit, M; Goldfarb, PS; Gray, TJB; Gibson, GG
      A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro

      XENOBIOTICA
    41. Lin, JH; Chiba, M; Baillie, TA
      Is the role of the small intestine in first-pass metabolism overemphasized?

      PHARMACOLOGICAL REVIEWS
    42. Damkier, P; Hansen, LL; Brosen, K
      Effect of fluvoxamine on the pharmacokinetics of quinidine

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    43. Fontana, RJ; Lown, KS; Paine, MF; Fortlage, L; Santella, RM; Felton, JS; Knize, MG; Greenberg, A; Watkins, PB
      Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers

      GASTROENTEROLOGY
    44. Tsunoda, SM; Velez, RL; von Moltke, LL; Greenblatt, DJ
      Differentiation of intestinal and hepatic cytochrome P450 3A activity withuse of midazolam as an in vivo probe: Effect of ketoconazole

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    45. Ball, SE; Scatina, JA; Kao, J; Ferron, GM; Fruncillo, R; Mayer, P; Weinryb, I; Guida, M; Hopkins, PJ; Warner, N; Hall, J
      Population distribution and effects on drug metabolism of a genetic variant in the 5 ' promotor region of CYP3A4

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    46. Verbeeck, RK; Horsmans, Y
      Effect of hepatic insufficiency on pharmacokinetics and drug dosing

      PHARMACY WORLD & SCIENCE
    47. THUMMEL KE; WILKINSON GR
      IN-VITRO AND IN-VIVO DRUG-INTERACTIONS INVOLVING HUMAN CYP3A

      Annual review of pharmacology and toxicology
    48. SEIDEGARD J; DAHLSTROM K; KULLBERG A
      EFFECT OF GRAPEFRUIT JUICE ON URINARY 6-BETA-HYDROXYCORTISOL CORTISOLEXCRETION/

      Clinical and experimental pharmacology and physiology
    49. TANAKA E
      CLINICAL IMPORTANCE OF NONGENETIC AND GENETIC CYTOCHROME-P450 FUNCTION-TESTS IN LIVER-DISEASE

      Journal of clinical pharmacy and therapeutics
    50. CARRILLO JA; RAMOS SI; AGUNDEZ JAG; MARTINEZ C; BENITEZ J
      ANALYSIS OF MIDAZOLAM AND METABOLITES IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - PROBE OF CYP3A

      Therapeutic drug monitoring
    51. Tsunoda, SM; Harris, RZ; Mroczkowski, PJ; Benet, LZ
      Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women

      JOURNAL OF CLINICAL PHARMACOLOGY
    52. Smith, DA; Abel, SM; Hyland, R; Jones, BC
      Human cytochrome P450s: selectivity and measurement in vivo

      XENOBIOTICA
    53. Pelkonen, O; Maenpaa, J; Taavitsainen, P; Rautio, A; Raunio, H
      Inhibition and induction of human cytochrome P450 (CYP) enzymes

      XENOBIOTICA
    54. NAKAZAWA Y; CHISUWA H; IKEGAMI T; HASHIKURA Y; TERADA M; KATSUYAMA Y; IWASAKI K; KAWASAKI S
      RELATIONSHIP BETWEEN IN-VIVO FK506 CLEARANCE AND IN-VITRO 13-DEMETHYLATION ACTIVITY IN LIVING-RELATED LIVER-TRANSPLANTATION

      Transplantation
    55. Gass, RJA; Gal, J; Fogle, PW; Detmar-Hanna, D; Gerber, JG
      Neither dapsone hydroxylation nor cortisol 6 beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    56. KASHUBA ADM; BERTINO JS; ROCCI ML; KULAWY RW; BECK DJ; NAFZIGER AN
      QUANTIFICATION OF 3-MONTH INTRAINDIVIDUAL VARIABILITY AND THE INFLUENCE OF SEX AND MENSTRUAL-CYCLE PHASE ON CYP3A ACTIVITY AS MEASURED BY PHENOTYPING WITH INTRAVENOUS MIDAZOLAM

      Clinical pharmacology and therapeutics
    57. WANDEL C; LANG CC; COWART DC; GIRARD AF; BRAMER S; FLOCKHART DA; WOOD AJJ
      EFFECT OF CYP3A INHIBITION ON VESNARINONE METABOLISM IN HUMANS

      Clinical pharmacology and therapeutics
    58. SLAMA JT; HANCOCK JL; RHO T; SAMBUCETTI L; BACHMANN KA
      INFLUENCE OF SOME NOVEL N-SUBSTITUTED AZOLES AND PYRIDINES ON RAT HEPATIC CYP3A ACTIVITY

      Biochemical pharmacology
    59. RILEY RJ; HOWBROOK D
      IN-VITRO ANALYSIS OF THE ACTIVITY OF THE MAJOR HUMAN HEPATIC CYP ENZYME (CYP3A4) USING [N-METHYL-C-14]-ERYTHROMYCIN

      Journal of pharmacological and toxicological methods
    60. AMEER B; WEINTRAUB RA
      DRUG-INTERACTIONS WITH GRAPEFRUIT JUICE

      Clinical pharmacokinetics
    61. WANG JS; WANG W; XIE HG; HUANG SL; ZHOU HH
      EFFECT OF TROLEANDOMYCIN ON THE PHARMACOKINETICS OF IMIPRAMINE IN CHINESE - THE ROLE OF CYP3A

      British journal of clinical pharmacology
    62. SPICER ST; LIDDLE C; CHAPMAN JR; BARCLAY P; NANKIVELL BJ; THOMAS P; OCONNELL PJ
      THE MECHANISM OF CYCLOSPORINE TOXICITY INDUCED BY CLARITHROMYCIN

      British journal of clinical pharmacology
    63. JAMISDOW CA; PEARL ML; WATKINS PB; BLAKE DS; KLECKER RW; COLLINS JM
      PREDICTING DRUG-INTERACTIONS IN-VIVO FROM EXPERIMENTS IN-VITRO - HUMAN STUDIES WITH PACLITAXEL AND KETOCONAZOLE

      American journal of clinical oncology
    64. WATKINS PB
      THE BARRIER FUNCTION OF CYP3A4 AND P-GLYCOPROTEIN IN THE SMALL-BOWEL

      Advanced drug delivery reviews
    65. HEBERT MF
      CONTRIBUTIONS OF HEPATIC AND INTESTINAL METABOLISM AND P-GLYCOPROTEINTO CYCLOSPORINE AND TACROLIMUS ORAL-DRUG DELIVERY

      Advanced drug delivery reviews
    66. KIVISTO KT; KROEMER HK
      USE OF PROBE DRUGS AS PREDICTORS OF DRUG-METABOLISM IN HUMANS

      Journal of clinical pharmacology
    67. BAILEY B; KLEIN J; KOREN G
      NONINVASIVE METHODS FOR DRUG MEASUREMENT IN PEDIATRICS

      The Pediatric clinics of North America
    68. LOWN KS; BAILEY DG; FONTANA RJ; JANARDAN SK; ADAIR CH; FORTLAGE LA; BROWN MB; GUO WS; WATKINS PB
      GRAPEFRUIT JUICE INCREASES FELODIPINE ORAL AVAILABILITY IN HUMANS BY DECREASING INTESTINAL CYP3A PROTEIN EXPRESSION

      The Journal of clinical investigation
    69. TRAN A; REY E; PONS G; ROUSSEAU M; DATHIS P; OLIVE G; MATHER GG; BISHOP FE; WURDEN CJ; LABROO R; TRAGER WF; KUNZE KL; THUMMEL KE; VINCENT JC; GILLARDIN JM; LEPAGE F; LEVY RH
      INFLUENCE OF STIRIPENTOL ON CYTOCHROME P450-MEDIATED METABOLIC PATHWAYS IN HUMANS - IN-VITRO AND IN-VIVO COMPARISON AND CALCULATION OF IN-VIVO INHIBITION CONSTANTS

      Clinical pharmacology and therapeutics
    70. LOWN KS; MAYO RR; LEICHTMAN AB; HSIAO HL; TURGEON DK; SCHMIEDLINREN P; BROWN MB; GUO WS; ROSSI SJ; BENET LZ; WATKINS PB
      ROLE OF INTESTINAL P-GLYCOPROTEIN (MDR1) IN INTERPATIENT VARIATION INTHE ORAL BIOAVAILABILITY OF CYCLOSPORINE

      Clinical pharmacology and therapeutics
    71. IATSIMIRSKAIA E; TULEBAEV S; STOROZHUK E; UTKIN I; SMITH D; GERBER N; KOUDRIAKOVA T
      METABOLISM OF RIFABUTIN IN HUMAN ENTEROCYTE AND LIVER-MICROSOMES - KINETIC-PARAMETERS, IDENTIFICATION OF ENZYME-SYSTEMS, AND DRUG-INTERACTIONS WITH MACROLIDES AND ANTIFUNGAL AGENTS

      Clinical pharmacology and therapeutics
    72. DARBAR D; DELLORTO S; MORIKE K; WILKINSON GR; RODEN DM
      DIETARY SALT INCREASES FIRST-PASS ELIMINATION OF ORAL QUINIDINE

      Clinical pharmacology and therapeutics
    73. GUITTON J; BURONFOSSE T; DESAGE M; LEPAPE A; BRAZIER JL; BEAUNE P
      POSSIBLE INVOLVEMENT OF MULTIPLE CYTOCHROME P450S IN FENTANYL AND SUFENTANIL METABOLISM AS OPPOSED TO ALFENTANIL

      Biochemical pharmacology
    74. KHARASCH ED; RUSSELL M; GARTON K; LENTZ G; BOWDLE TA; COX K
      ASSESSMENT OF CYTOCHROME-P450 3A4 ACTIVITY DURING THE MENSTRUAL-CYCLEUSING ALFENTANIL AS A NONINVASIVE PROBE

      Anesthesiology
    75. HORSMANS Y
      MAJOR CYTOCHROME-P-450 FAMILIES - IMPLICATIONS IN HEALTH AND LIVER-DISEASES

      Acta Gastro-Enterologica Belgica
    76. JANARDAN SK; LOWN KS; SCHMIEDLINREN P; THUMMEL KE; WATKINS PB
      SELECTIVE EXPRESSION OF CYP3A5 AND NOT CYP3A4 IN HUMAN BLOOD

      Pharmacogenetics
    77. TSUNODA SM; AWEEKA FT
      THE USE OF THERAPEUTIC DRUG-MONITORING TO OPTIMIZE IMMUNOSUPPRESSIVE THERAPY

      Clinical pharmacokinetics
    78. WACHER VJ; SALPHATI L; BENET LZ
      ACTIVE SECRETION AND ENTEROCYTIC DRUG-METABOLISM BARRIERS TO DRUG ABSORPTION

      Advanced drug delivery reviews
    79. PEREZ EA; BUCKWALTER CA; REID JP
      COMBINATIONS OF PACLITAXEL AND ETOPOSIDE IN THE TREATMENT OF LUNG-CANCER

      Seminars in oncology
    80. IRSHAID Y; BRANCH RA; ADEDOYIN A
      METABOLIC INTERACTIONS OF PUTATIVE CYTOCHROME P4503A SUBSTRATES WITH ALTERNATIVE PATHWAYS OF DAPSONE METABOLISM IN HUMAN LIVER-MICROSOMES

      Drug metabolism and disposition
    81. YEATES RA; SCHARPF F; LAUFEN H; ZIMMERMANN T
      SCREENING FOR CYTOCHROME-P450 3A IN MAN - STUDIES WITH MIDAZOLAM AND NIFEDIPINE

      Journal of Pharmacy and Pharmacology
    82. THOMPSON GA; STPETER JV; HEISE MA; HOROWITZ ZD; SALYERS GC; CHARLES TT; BREZOVIC C; RUSSELL DA; SKARE JA; POWELL JH
      ASSESSMENT OF DOXYLAMINE INFLUENCE ON MIXED-FUNCTION OXIDASE ACTIVITYUPON MULTIPLE-DOSE ORAL-ADMINISTRATION TO NORMAL VOLUNTEERS

      Journal of pharmaceutical sciences
    83. HICKEY PL; MCLEAN AJ; ANGUS PW; CHOO EF; MORGAN DJ
      INCREASED SENSITIVITY OF PROPRANOLOL CLEARANCE TO REDUCED OXYGEN DELIVERY IN THE ISOLATED-PERFUSED CIRRHOTIC RAT-LIVER

      Gastroenterology
    84. JONES DR; GORSKI JC; HAEHNER BD; OMARA EM; HALL SD
      DETERMINATION OF CYTOCHROME-P450 3A4 5 ACTIVITY IN-VIVO WITH DEXTROMETHORPHAN N-DEMETHYLATION/

      Clinical pharmacology and therapeutics
    85. TATEISHI T; KRIVORUK Y; UENG YF; WOOD AJJ; GUENGERICH FP; WOOD M
      IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P-450 3A4 AS THE ENZYME RESPONSIBLE FOR FENTANYL AND SUFENTANIL N-DEALKYLATION

      Anesthesia and analgesia
    86. CARLSTON JA
      DRUG-INTERACTIONS AND THE CYTOCHROME-P-450 ENZYMES

      Pediatric asthma, allergy & immunology
    87. GEORGE J; MURRAY M; BYTH K; FARRELL GC
      DIFFERENTIAL ALTERATIONS OF CYTOCHROME-P450 PROTEINS IN LIVERS FROM PATIENTS WITH SEVERE CHRONIC LIVER-DISEASE

      Hepatology
    88. LABROO RB; THUMMEL KE; KUNZE KL; PODOLL T; TRAGER WF; KHARASCH ED
      CATALYTIC ROLE OF CYTOCHROME P4503A4 IN MULTIPLE PATHWAYS OF ALFENTANIL METABOLISM

      Drug metabolism and disposition
    89. TANAKA E; ISHIKAWA A; MISAWA S
      CHANGES IN THE METABOLISM OF 3 MODEL SUBSTRATES CATALYZED BY DIFFERENT P450 ISOZYMES WHEN ADMINISTERED AS A COCKTAIL TO THE CARBON TETRACHLORIDE-INTOXICATED RAT

      Xenobiotica
    90. SCHUETZ EG; FURUYA KN; SCHUETZ JD
      INTERINDIVIDUAL VARIATION IN EXPRESSION OF P-GLYCOPROTEIN IN NORMAL HUMAN LIVER AND SECONDARY HEPATIC NEOPLASMS

      The Journal of pharmacology and experimental therapeutics
    91. CHRISTIANS U; SEWING KF
      ALTERNATIVE CYCLOSPORINE METABOLIC PATHWAYS AND TOXICITY

      Clinical biochemistry
    92. WATKINS PB
      NONINVASIVE TESTS OF CYP3A ENZYMES

      Pharmacogenetics
    93. SCHUETZ JD; BEACH DL; GUZELIAN PS
      SELECTIVE EXPRESSION OF CYTOCHROME-P450 CYP3A MESSENGER-RNAS IN EMBRYONIC AND ADULT HUMAN LIVER

      Pharmacogenetics
    94. GONZALEZ FJ; GELBOIN HV
      ROLE OF HUMAN CYTOCHROMES P450 IN THE METABOLIC-ACTIVATION OF CHEMICAL CARCINOGENS AND TOXINS

      Drug metabolism reviews
    95. BROCKMOLLER J; ROOTS I
      ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS

      Clinical pharmacokinetics
    96. CAKALOGLU Y; TREDGER JM; DEVLIN J; WILLIAMS R
      IMPORTANCE OF CYTOCHROME P-450IIIA ACTIVITY IN DETERMINING DOSAGE ANDBLOOD-LEVELS OF FK-506 AND CYCLOSPORINE IN LIVER-TRANSPLANT RECIPIENTS

      Hepatology
    97. SHIFFMAN ML; LUKETIC VA; SANYAL AJ; DUCKWORTH PF; PURDUM PP; CONTOS MJ; MILLS AS; EDINBORO LE; POKLIS A
      HEPATIC LIDOCAINE METABOLISM AND LIVER HISTOLOGY IN PATIENTS WITH CHRONIC HEPATITIS AND CIRRHOSIS

      Hepatology
    98. THUMMEL KE; SHEN DD; PODOLL TD; KUNZE KL; TRAGER WF; HARTWELL PS; RAISYS VA; MARSH CL; MCVICAR JP; BARR DM; PERKINS JD; CARITHERS RL
      USE OF MIDAZOLAM AS A HUMAN CYTOCHROME-P450 3A PROBE .1. IN-VITRO IN-VIVO CORRELATION IN LIVER-TRANSPLANT PATIENTS

      The Journal of pharmacology and experimental therapeutics
    99. TURGEON DK; LEICHTMAN AB; LOWN KS; NORMOLLE DP; DEEB GM; MERION RM; WATKINS PB
      P450 3A ACTIVITY AND CYCLOSPORINE DOSING IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS

      Clinical pharmacology and therapeutics
    100. GORSKI JC; HALL SD; VANDENBRANDEN M; WRIGHTON SA; JONES DR
      REGIOSELECTIVE BIOTRANSFORMATION OF MIDAZOLAM BY MEMBERS OF THE HUMANCYTOCHROME-P450-3A (CYP3A) SUBFAMILY

      Biochemical pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/06/20 alle ore 07:59:06